메뉴 건너뛰기




Volumn 11, Issue 7, 2015, Pages 1573-1584

Oncolytic viruses: From bench to bedside with a focus on safety

Author keywords

Cancer; Environment; Immunotherapy; Oncolytic virotherapy; Oncolytic virus; Review; Safety; Shedding

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOLYTIC VIRUS; TRANSFORMING GROWTH FACTOR ALPHA; Y BOX BINDING PROTEIN 1;

EID: 84944461168     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1037058     Document Type: Review
Times cited : (103)

References (150)
  • 2
    • 33645787026 scopus 로고    scopus 로고
    • Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor
    • PMID:16554374
    • Zhou G, Roizman B. Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A 2006; 103:5508-13; PMID:16554374; http://dx. doi. org/10. 1073/pnas. 0601258103
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 5508-5513
    • Zhou, G.1    Roizman, B.2
  • 3
    • 53749099520 scopus 로고    scopus 로고
    • Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2
    • PMID:18684832
    • Menotti L, Cerretani A, Hengel H, Campadelli- Fiume G. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 2008; 82:10153-61; PMID:18684832; http:// dx. doi. org/10. 1128/JVI. 01133-08
    • (2008) J Virol , vol.82 , pp. 10153-10161
    • Menotti, L.1    Cerretani, A.2    Hengel, H.3    Campadelli-Fiume, G.4
  • 4
    • 0037069501 scopus 로고    scopus 로고
    • Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction
    • PMID:12417744
    • Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A 2002; 99:15124-9; PMID:12417744; http://dx. doi. org/10. 1073/pnas. 232588699
    • (2002) Proc Natl Acad Sci U S A , vol.99 , pp. 15124-15129
    • Zhou, G.1    Ye, G.J.2    Debinski, W.3    Roizman, B.4
  • 5
    • 33646746200 scopus 로고    scopus 로고
    • A herpes simplex virus recombinant that exhibits a singlechain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors
    • PMID:16699034
    • Menotti L, Cerretani A, Campadelli-Fiume G. A herpes simplex virus recombinant that exhibits a singlechain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol 2006; 80:5531-9; PMID:16699034; http://dx. doi. org/10. 1128/JVI. 02725-05
    • (2006) J Virol , vol.80 , pp. 5531-5539
    • Menotti, L.1    Cerretani, A.2    Campadelli-Fiume, G.3
  • 6
    • 77955925502 scopus 로고    scopus 로고
    • Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells
    • PMID:20508670
    • Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Ther 2010; 17:655-63; PMID:20508670; http://dx. doi. org/10. 1038/cgt. 2010. 22
    • (2010) Cancer Gene Ther , vol.17 , pp. 655-663
    • Grandi, P.1    Fernandez, J.2    Szentirmai, O.3    Carter, R.4    Gianni, D.5    Sena-Esteves, M.6    Breakefield, X.O.7
  • 7
    • 16844366956 scopus 로고    scopus 로고
    • An oncolytic HSV-1 mutant expressing ICP34. 5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor
    • PMID:15805284
    • Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34. 5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005; 65:2832-9; PMID:15805284; http://dx. doi. org/10. 1158/0008-5472. CAN-04-3227
    • (2005) Cancer Res , vol.65 , pp. 2832-2839
    • Kambara, H.1    Okano, H.2    Chiocca, E.A.3    Saeki, Y.4
  • 8
    • 85017731934 scopus 로고    scopus 로고
    • Amgen. http://www. amgen. com/media/media_pr_de tail. jsp?releaseID=1962767
    • Amgen
  • 9
    • 0034922940 scopus 로고    scopus 로고
    • Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates
    • PMID:11387063
    • Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001; 12:999-1010; PMID:11387063; http://dx. doi. org/10. 1089/ 104303401750195944
    • (2001) Hum Gene Ther , vol.12 , pp. 999-1010
    • Varghese, S.1    Newsome, J.T.2    Rabkin, S.D.3    McGeagh, K.4    Mahoney, D.5    Nielsen, P.6    Todo, T.7    Martuza, R.L.8
  • 10
    • 9944246008 scopus 로고    scopus 로고
    • Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates
    • PMID:15306839
    • Wolfe D, Niranjan A, Trichel A, Wiley C, Ozuer A, Kanal E, Kondziolka D, Krisky D, Goss J, Deluca N, et al. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Ther 2004; 11:1675-84; PMID:15306839; http://dx. doi. org/10. 1038/sj. gt. 3302336
    • (2004) Gene Ther , vol.11 , pp. 1675-1684
    • Wolfe, D.1    Niranjan, A.2    Trichel, A.3    Wiley, C.4    Ozuer, A.5    Kanal, E.6    Kondziolka, D.7    Krisky, D.8    Goss, J.9    Deluca, N.10
  • 11
    • 12944315014 scopus 로고    scopus 로고
    • Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
    • PMID:10845725
    • Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7:867-74; PMID:10845725; http:// dx. doi. org/10. 1038/sj. gt. 3301205
    • (2000) Gene Ther , vol.7 , pp. 867-874
    • Markert, J.M.1    Medlock, M.D.2    Rabkin, S.D.3    Gillespie, G.Y.4    Todo, T.5    Hunter, W.D.6    Palmer, C.A.7    Feigenbaum, F.8    Tornatore, C.9    Tufaro, F.10
  • 13
    • 33845336115 scopus 로고    scopus 로고
    • A phase I study of OncoVEXGMCSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
    • PMID:17121894
    • Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, et al. A phase I study of OncoVEXGMCSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12:6737-47; PMID:17121894; http://dx. doi. org/10. 1158/1078- 0432. CCR-06-0759
    • (2006) Clin Cancer Res , vol.12 , pp. 6737-6747
    • Hu, J.C.1    Coffin, R.S.2    Davis, C.J.3    Graham, N.J.4    Groves, N.5    Guest, P.J.6    Harrington, K.J.7    James, N.D.8    Love, C.A.9    McNeish, I.10
  • 14
    • 73349133717 scopus 로고    scopus 로고
    • Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma
    • PMID:19884534
    • Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763-71; PMID:19884534; http://dx. doi. org/10. 1200/JCO. 2009. 24. 3675
    • (2009) J Clin Oncol , vol.27 , pp. 5763-5771
    • Senzer, N.N.1    Kaufman, H.L.2    Amatruda, T.3    Nemunaitis, M.4    Reid, T.5    Daniels, G.6    Gonzalez, R.7    Glaspy, J.8    Whitman, E.9    Harrington, K.10
  • 15
    • 77955104827 scopus 로고    scopus 로고
    • Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck
    • PMID:20670951
    • Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish IA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16:4005-15; PMID:20670951; http://dx. doi. org/ 10. 1158/1078-0432. CCR-10-0196
    • (2010) Clin Cancer Res , vol.16 , pp. 4005-4015
    • Harrington, K.J.1    Hingorani, M.2    Tanay, M.A.3    Hickey, J.4    Bhide, S.A.5    Clarke, P.M.6    Renouf, L.C.7    Thway, K.8    Sibtain, A.9    McNeish, I.A.10
  • 16
    • 77957844552 scopus 로고    scopus 로고
    • Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver
    • PMID:20486770
    • Geevarghese SK, Geller DA, de Haan HA, Horer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21:1119-28; PMID:20486770; http://dx. doi. org/10. 1089/ hum. 2010. 020
    • (2010) Hum Gene Ther , vol.21 , pp. 1119-1128
    • Geevarghese, S.K.1    Geller, D.A.2    de Haan, H.A.3    Horer, M.4    Knoll, A.E.5    Mescheder, A.6    Nemunaitis, J.7    Reid, T.R.8    Sze, D.Y.9    Tanabe, K.K.10
  • 17
    • 0032821242 scopus 로고    scopus 로고
    • Mechanism and application of genetic recombination in herpesviruses
    • PMID:10479778
    • Umene K. Mechanism and application of genetic recombination in herpesviruses. Rev Med Virol 1999; 9:171-82; PMID:10479778; http://dx. doi. org/ 10. 1002/(SICI)1099-1654(199907/09)9:3%3c171:: AID-RMV243%3e3. 0. CO;2-A
    • (1999) Rev Med Virol , vol.9 , pp. 171-182
    • Umene, K.1
  • 18
    • 0031868959 scopus 로고    scopus 로고
    • The second-site mutation in the herpes simplex virus recombinants lacking the gamma134. 5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha
    • PMID:9696792
    • Cassady KA, Gross M, Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134. 5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 1998; 72:7005-11; PMID:9696792
    • (1998) J Virol , vol.72 , pp. 7005-7011
    • Cassady, K.A.1    Gross, M.2    Roizman, B.3
  • 19
    • 57049146779 scopus 로고    scopus 로고
    • Clinical features and treatment of adenovirus infections
    • PMID:18655013
    • Lenaerts L, De Clercq E, Naesens L. Clinical features and treatment of adenovirus infections. Rev Med Virol 2008; 18:357-74; PMID:18655013; http://dx. doi. org/10. 1002/rmv. 589
    • (2008) Rev Med Virol , vol.18 , pp. 357-374
    • Lenaerts, L.1    De Clercq, E.2    Naesens, L.3
  • 20
    • 79952945559 scopus 로고    scopus 로고
    • Oncolytic adenoviruses for the treatment of human cancer: Focus on translational and clinical data
    • PMID:21126047
    • Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011; 8:12-28; PMID:21126047; http://dx. doi. org/ 10. 1021/mp100219n
    • (2011) Mol Pharm , vol.8 , pp. 12-28
    • Pesonen, S.1    Kangasniemi, L.2    Hemminki, A.3
  • 22
    • 19944363519 scopus 로고    scopus 로고
    • Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
    • PMID:15607965
    • O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6:611-23; PMID:15607965; http://dx. doi. org/ 10. 1016/j. ccr. 2004. 11. 012
    • (2004) Cancer Cell , vol.6 , pp. 611-623
    • O'Shea, C.C.1    Johnson, L.2    Bagus, B.3    Choi, S.4    Nicholas, C.5    Shen, A.6    Boyle, L.7    Pandey, K.8    Soria, C.9    Kunich, J.10
  • 24
    • 19044386714 scopus 로고    scopus 로고
    • Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents
    • PMID:12086848
    • Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1:325-37; PMID:12086848; http://dx. doi. org/10. 1016/S1535- 6108(02)00060-0
    • (2002) Cancer Cell , vol.1 , pp. 325-337
    • Johnson, L.1    Shen, A.2    Boyle, L.3    Kunich, J.4    Pandey, K.5    Lemmon, M.6    Hermiston, T.7    Giedlin, M.8    McCormick, F.9    Fattaey, A.10
  • 25
    • 0036708228 scopus 로고    scopus 로고
    • Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy
    • PMID:12189522
    • Kim J, Cho JY, Kim JH, Jung KC, Yun CO. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther 2002; 9:725-36; PMID:12189522; http://dx. doi. org/ 10. 1038/sj. cgt. 7700494
    • (2002) Cancer Gene Ther , vol.9 , pp. 725-736
    • Kim, J.1    Cho, J.Y.2    Kim, J.H.3    Jung, K.C.4    Yun, C.O.5
  • 26
    • 0141592775 scopus 로고    scopus 로고
    • Rasdependent oncolysis with an adenovirus VAI mutant
    • PMID:14500393
    • Cascallo M, Capella G, Mazo A, Alemany R. Rasdependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003; 63:5544-50; PMID:14500393
    • (2003) Cancer Res , vol.63 , pp. 5544-5550
    • Cascallo, M.1    Capella, G.2    Mazo, A.3    Alemany, R.4
  • 28
    • 0034077666 scopus 로고    scopus 로고
    • Replication-selective adenoviruses as oncolytic agents
    • PMID:10749561
    • Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105:847-51; PMID:10749561; http://dx. doi. org/10. 1172/ JCI9762
    • (2000) J Clin Invest , vol.105 , pp. 847-851
    • Heise, C.1    Kirn, D.H.2
  • 29
    • 0142124908 scopus 로고    scopus 로고
    • Virotherapeutics: Conditionally replicative adenoviruses for viral oncolysis
    • PMID:14501378
    • Nettelbeck DM. Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003; 14:577-84; PMID:14501378; http://dx. doi. org/10. 1097/00001813-200309000-00001
    • (2003) Anticancer Drugs , vol.14 , pp. 577-584
    • Nettelbeck, D.M.1
  • 30
    • 76749116217 scopus 로고    scopus 로고
    • Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo
    • PMID:20085660
    • Li X, Liu Y, Wen Z, Li C, Lu H, Tian M, Jin K, Sun L, Gao P, Yang E, et al. Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer 2010; 9:10; PMID:20085660; http://dx. doi. org/10. 1186/1476- 4598-9-10
    • (2010) Mol Cancer , vol.9 , pp. 10
    • Li, X.1    Liu, Y.2    Wen, Z.3    Li, C.4    Lu, H.5    Tian, M.6    Jin, K.7    Sun, L.8    Gao, P.9    Yang, E.10
  • 31
    • 84899538705 scopus 로고    scopus 로고
    • A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs
    • PMID:24722669
    • Gao Q, Chen C, Ji T, Wu P, Han Z, Fang H, Li F, Liu Y, Hu W, Gong D, et al. A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs. PLoS One 2014; 9:e94050; PMID:24722669; http://dx. doi. org/10. 1371/journal. pone. 0094050
    • (2014) PLoS One , vol.9
    • Gao, Q.1    Chen, C.2    Ji, T.3    Wu, P.4    Han, Z.5    Fang, H.6    Li, F.7    Liu, Y.8    Hu, W.9    Gong, D.10
  • 33
    • 84869095632 scopus 로고    scopus 로고
    • A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer
    • PMID:23088985
    • Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 2012; 188:2391-7; PMID:23088985; http://dx. doi. org/10. 1016/j. juro. 2012. 07. 097
    • (2012) J Urol , vol.188 , pp. 2391-2397
    • Burke, J.M.1    Lamm, D.L.2    Meng, M.V.3    Nemunaitis, J.J.4    Stephenson, J.J.5    Arseneau, J.C.6    Aimi, J.7    Lerner, S.8    Yeung, A.W.9    Kazarian, T.10
  • 36
    • 0036710714 scopus 로고    scopus 로고
    • The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells
    • PMID:12204675
    • Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT, Douglas JT. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002; 38:1917-26; PMID:12204675; http://dx. doi. org/10. 1016/S0959- 8049(02)00131-4
    • (2002) Eur J Cancer , vol.38 , pp. 1917-1926
    • Kim, M.1    Zinn, K.R.2    Barnett, B.G.3    Sumerel, L.A.4    Krasnykh, V.5    Curiel, D.T.6    Douglas, J.T.7
  • 37
    • 0034980914 scopus 로고    scopus 로고
    • Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver
    • PMID:11162308
    • Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001; 3:28-35; PMID:11162308; http://dx. doi. org/ 10. 1006/mthe. 2000. 0227
    • (2001) Mol Ther , vol.3 , pp. 28-35
    • Tao, N.1    Gao, G.P.2    Parr, M.3    Johnston, J.4    Baradet, T.5    Wilson, J.M.6    Barsoum, J.7    Fawell, S.E.8
  • 38
    • 0034830243 scopus 로고    scopus 로고
    • CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors
    • PMID:11571572
    • Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001; 8:1347-53; PMID:11571572; http://dx. doi. org/10. 1038/sj. gt. 3301515
    • (2001) Gene Ther , vol.8 , pp. 1347-1353
    • Alemany, R.1    Curiel, D.T.2
  • 39
    • 0035989025 scopus 로고    scopus 로고
    • In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor
    • PMID:12027562
    • Smith T, Idamakanti N, Kylefjord H, Rollence M, King L, Kaloss M, Kaleko M, Stevenson SC. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther 2002; 5:770-9; PMID:12027562; http://dx. doi. org/ 10. 1006/mthe. 2002. 0613
    • (2002) Mol Ther , vol.5 , pp. 770-779
    • Smith, T.1    Idamakanti, N.2    Kylefjord, H.3    Rollence, M.4    King, L.5    Kaloss, M.6    Kaleko, M.7    Stevenson, S.C.8
  • 41
    • 77956585904 scopus 로고    scopus 로고
    • Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor £ binding, decreases liver tropism, and improves antitumor efficacy
    • PMID:20736345
    • Short JJ, Rivera AA, Wu H, Walter MR, Yamamoto M, Mathis JM, Curiel DT. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor £ binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther 2010; 9:2536-44; PMID:20736345; http://dx. doi. org/10. 1158/1535-7163. MCT-10-0332
    • (2010) Mol Cancer Ther , vol.9 , pp. 2536-2544
    • Short, J.J.1    Rivera, A.A.2    Wu, H.3    Walter, M.R.4    Yamamoto, M.5    Mathis, J.M.6    Curiel, D.T.7
  • 42
    • 79952207509 scopus 로고    scopus 로고
    • Tropism-modification strategies for targeted gene delivery using adenoviral vectors
    • PMID:21994621
    • Coughlan L, Alba R, Parker AL, Bradshaw AC, McNeish IA, Nicklin SA, Baker AH. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2010; 2:2290-355; PMID:21994621; http://dx. doi. org/10. 3390/ v2102290
    • (2010) Viruses , vol.2 , pp. 2290-2355
    • Coughlan, L.1    Alba, R.2    Parker, A.L.3    Bradshaw, A.C.4    McNeish, I.A.5    Nicklin, S.A.6    Baker, A.H.7
  • 44
    • 77956836329 scopus 로고    scopus 로고
    • Development of a targeted gene vector platform based on simian adenovirus serotype 24
    • PMID:20631120
    • Belousova N, Mikheeva G, Xiong C, Soghomonian S, Young D, Le Roux L, Naff K, Bidaut L, Wei W, Li C, et al. Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol 2010; 84:10087-101; PMID:20631120; http://dx. doi. org/10. 1128/JVI. 02425-09
    • (2010) J Virol , vol.84 , pp. 10087-10101
    • Belousova, N.1    Mikheeva, G.2    Xiong, C.3    Soghomonian, S.4    Young, D.5    Le Roux, L.6    Naff, K.7    Bidaut, L.8    Wei, W.9    Li, C.10
  • 45
    • 61649121877 scopus 로고    scopus 로고
    • Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model
    • PMID:19211122
    • Sharma A, Bangari DS, Tandon M, Pandey A, HogenEsch H, Mittal SK. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 2009; 386:44-54; PMID:19211122; http://dx. doi. org/10. 1016/j. virol. 2009. 01. 008
    • (2009) Virology , vol.386 , pp. 44-54
    • Sharma, A.1    Bangari, D.S.2    Tandon, M.3    Pandey, A.4    HogenEsch, H.5    Mittal, S.K.6
  • 46
    • 49149090311 scopus 로고    scopus 로고
    • Directed evolution generates a novel oncolytic virus for the treatment of colon cancer
    • PMID:18560559
    • Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 2008; 3: e2409; PMID:18560559; http://dx. doi. org/10. 1371/ journal. pone. 0002409
    • (2008) PLoS One , vol.3
    • Kuhn, I.1    Harden, P.2    Bauzon, M.3    Chartier, C.4    Nye, J.5    Thorne, S.6    Reid, T.7    Ni, S.8    Lieber, A.9    Fisher, K.10
  • 47
    • 84871919798 scopus 로고    scopus 로고
    • Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library
    • PMID:23032977
    • Miura Y, Yamasaki S, Davydova J, Brown E, Aoki K, Vickers S, Yamamoto M. Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library. Mol Ther 2013; 21:139-48; PMID:23032977; http://dx. doi. org/ 10. 1038/mt. 2012. 205
    • (2013) Mol Ther , vol.21 , pp. 139-148
    • Miura, Y.1    Yamasaki, S.2    Davydova, J.3    Brown, E.4    Aoki, K.5    Vickers, S.6    Yamamoto, M.7
  • 48
    • 0036828125 scopus 로고    scopus 로고
    • Hepatic arterial infusion of a replication- selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints
    • PMID:12414631
    • Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, et al. Hepatic arterial infusion of a replication- selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62:6070-9; PMID:12414631
    • (2002) Cancer Res , vol.62 , pp. 6070-6079
    • Reid, T.1    Galanis, E.2    Abbruzzese, J.3    Sze, D.4    Wein, L.M.5    Andrews, J.6    Randlev, B.7    Heise, C.8    Uprichard, M.9    Hatfield, M.10
  • 49
    • 78049468477 scopus 로고    scopus 로고
    • A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases
    • PMID:20978148
    • Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, Kuo H, Saddekni S, Stockard CR, Grizzle WE, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010; 16:5277-87; PMID:20978148; http://dx. doi. org/10. 1158/1078-0432. CCR-10-0791
    • (2010) Clin Cancer Res , vol.16 , pp. 5277-5287
    • Kimball, K.J.1    Preuss, M.A.2    Barnes, M.N.3    Wang, M.4    Siegal, G.P.5    Wan, W.6    Kuo, H.7    Saddekni, S.8    Stockard, C.R.9    Grizzle, W.E.10
  • 50
    • 84857505900 scopus 로고    scopus 로고
    • Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors
    • PMID:21630267
    • Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012; 130:1937- 47; PMID:21630267; http://dx. doi. org/10. 1002/ ijc. 26216
    • (2012) Int J Cancer , vol.130 , pp. 1937-1947
    • Pesonen, S.1    Diaconu, I.2    Cerullo, V.3    Escutenaire, S.4    Raki, M.5    Kangasniemi, L.6    Nokisalmi, P.7    Dotti, G.8    Guse, K.9    Laasonen, L.10
  • 51
    • 77954530690 scopus 로고    scopus 로고
    • Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors
    • PMID:20237509
    • Pesonen S, Nokisalmi P, Escutenaire S, Sarkioja M, Raki M, Cerullo V, Kangasniemi L, Laasonen L, Ribacka C, Guse K, et al. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 2010; 17:892-904; PMID:20237509; http://dx. doi. org/10. 1038/ gt. 2010. 17
    • (2010) Gene Ther , vol.17 , pp. 892-904
    • Pesonen, S.1    Nokisalmi, P.2    Escutenaire, S.3    Sarkioja, M.4    Raki, M.5    Cerullo, V.6    Kangasniemi, L.7    Laasonen, L.8    Ribacka, C.9    Guse, K.10
  • 54
    • 84882452568 scopus 로고    scopus 로고
    • A phase I clinical trial of Ad5/ 3-Delta24, a novel serotype-chimeric, infectivityenhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
    • PMID:23756180
    • Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, Bae S, Singh KP, Siegal GP, Curiel DT, et al. A phase I clinical trial of Ad5/ 3-Delta24, a novel serotype-chimeric, infectivityenhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol 2013; 130:518-24; PMID:23756180; http://dx. doi. org/10. 1016/j. ygyno. 2013. 06. 003
    • (2013) Gynecol Oncol , vol.130 , pp. 518-524
    • Kim, K.H.1    Dmitriev, I.P.2    Saddekni, S.3    Kashentseva, E.A.4    Harris, R.D.5    Aurigemma, R.6    Bae, S.7    Singh, K.P.8    Siegal, G.P.9    Curiel, D.T.10
  • 56
    • 76349086193 scopus 로고    scopus 로고
    • A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors
    • PMID:19935775
    • Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010; 18:429-34; PMID:19935775; http://dx. doi. org/ 10. 1038/mt. 2009. 262
    • (2010) Mol Ther , vol.18 , pp. 429-434
    • Nemunaitis, J.1    Tong, A.W.2    Nemunaitis, M.3    Senzer, N.4    Phadke, A.P.5    Bedell, C.6    Adams, N.7    Zhang, Y.A.8    Maples, P.B.9    Chen, S.10
  • 59
    • 51649128840 scopus 로고    scopus 로고
    • Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597
    • PMID:18757331
    • Keedy V, Wang W, Schiller J, Chada S, Slovis B, Coffee K, Worrell J, Thet LA, Johnson DH, Carbone DP. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol 2008; 26:4166-71; PMID:18757331; http:// dx. doi. org/10. 1200/JCO. 2007. 15. 6927
    • (2008) J Clin Oncol , vol.26 , pp. 4166-4171
    • Keedy, V.1    Wang, W.2    Schiller, J.3    Chada, S.4    Slovis, B.5    Coffee, K.6    Worrell, J.7    Thet, L.A.8    Johnson, D.H.9    Carbone, D.P.10
  • 60
    • 67650327240 scopus 로고    scopus 로고
    • Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A pilot phase II trial
    • PMID:19287305
    • Tian G, Liu J, Zhou JS, Chen W. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anticancer Drugs 2009; 20:389- 95; PMID:19287305; http://dx. doi. org/10. 1097/ CAD. 0b013e32832a2df9
    • (2009) Anticancer Drugs , vol.20 , pp. 389-395
    • Tian, G.1    Liu, J.2    Zhou, J.S.3    Chen, W.4
  • 61
    • 68949197421 scopus 로고    scopus 로고
    • Phase I and biodistribution study of recombinant adenovirus vectormediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors
    • PMID:19363470
    • Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R, Liao H, Zhao HY, Zhang Y, Guan ZZ, et al. Phase I and biodistribution study of recombinant adenovirus vectormediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009; 16:723-30; PMID:19363470; http://dx. doi. org/10. 1038/cgt. 2009. 19
    • (2009) Cancer Gene Ther , vol.16 , pp. 723-730
    • Xu, F.1    Li, S.2    Li, X.L.3    Guo, Y.4    Zou, B.Y.5    Xu, R.6    Liao, H.7    Zhao, H.Y.8    Zhang, Y.9    Guan, Z.Z.10
  • 62
    • 33947702021 scopus 로고    scopus 로고
    • Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer
    • discussion . e9-10 PMID:17403430
    • Page JG, Tian B, Schweikart K, Tomaszewski J, Harris R, Broadt T, Polley-Nelson J, Noker PE, Wang M, Makhija S, et al. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 2007; 196:389. e1-9; discussion . e9-10; PMID:17403430; http://dx. doi. org/10. 1016/j. ajog. 2006. 12. 016
    • (2007) Am J Obstet Gynecol , vol.196 , pp. 389.e1-389.e9
    • Page, J.G.1    Tian, B.2    Schweikart, K.3    Tomaszewski, J.4    Harris, R.5    Broadt, T.6    Polley-Nelson, J.7    Noker, P.E.8    Wang, M.9    Makhija, S.10
  • 64
    • 35148855074 scopus 로고    scopus 로고
    • An inventory of shedding data from clinical gene therapy trials
    • PMID:17880045
    • Schenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein LC. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007; 9:910-21; PMID:17880045; http://dx. doi. org/ 10. 1002/jgm. 1096
    • (2007) J Gene Med , vol.9 , pp. 910-921
    • Schenk-Braat, E.A.1    van Mierlo, M.M.2    Wagemaker, G.3    Bangma, C.H.4    Kaptein, L.C.5
  • 65
    • 69249213616 scopus 로고    scopus 로고
    • Computational analysis of human adenovirus type 22 provides evidence for recombination among species D human adenoviruses in the penton base gene
    • PMID:19553309
    • Robinson CM, Rajaiya J, Walsh MP, Seto D, Dyer DW, Jones MS, Chodosh J. Computational analysis of human adenovirus type 22 provides evidence for recombination among species D human adenoviruses in the penton base gene. J Virol 2009; 83:8980-5; PMID:19553309; http://dx. doi. org/10. 1128/ JVI. 00786-09
    • (2009) J Virol , vol.83 , pp. 8980-8985
    • Robinson, C.M.1    Rajaiya, J.2    Walsh, M.P.3    Seto, D.4    Dyer, D.W.5    Jones, M.S.6    Chodosh, J.7
  • 66
    • 66749181110 scopus 로고    scopus 로고
    • Evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis
    • PMID:19492050
    • Walsh MP, Chintakuntlawar A, Robinson CM, Madisch I, Harrach B, Hudson NR, Schnurr D, Heim A, Chodosh J, Seto D, et al. Evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis. PLoS One 2009; 4: e5635; PMID:19492050; http://dx. doi. org/10. 1371/ journal. pone. 0005635
    • (2009) PLoS One , vol.4
    • Walsh, M.P.1    Chintakuntlawar, A.2    Robinson, C.M.3    Madisch, I.4    Harrach, B.5    Hudson, N.R.6    Schnurr, D.7    Heim, A.8    Chodosh, J.9    Seto, D.10
  • 67
    • 84886303993 scopus 로고    scopus 로고
    • Homologous recombination in E3 genes of human adenovirus species D
    • PMID:24027303
    • Singh G, Robinson CM, Dehghan S, Jones MS, Dyer DW, Seto D, Chodosh J. Homologous recombination in E3 genes of human adenovirus species D. J Virol 2013; 87:12481-8; PMID:24027303; http://dx. doi. org/10. 1128/JVI. 01927-13
    • (2013) J Virol , vol.87 , pp. 12481-12488
    • Singh, G.1    Robinson, C.M.2    Dehghan, S.3    Jones, M.S.4    Dyer, D.W.5    Seto, D.6    Chodosh, J.7
  • 68
    • 0037333202 scopus 로고    scopus 로고
    • Measles: Not just another viral exanthem
    • PMID:12620751
    • Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet 2003; 361:763-73; PMID:12620751; http://dx. doi. org/10. 1016/S0140- 6736(03)12661-X
    • (2003) Lancet , vol.361 , pp. 763-773
    • Duke, T.1    Mgone, C.S.2
  • 69
    • 58249115335 scopus 로고    scopus 로고
    • Measles: Old vaccines, new vaccines
    • PMID:19203111
    • Griffin DE, Pan CH. Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol 2009; 330:191- 212; PMID:19203111
    • (2009) Curr Top Microbiol Immunol , vol.330 , pp. 191-212
    • Griffin, D.E.1    Pan, C.H.2
  • 70
    • 84863543763 scopus 로고    scopus 로고
    • Attenuated oncolytic measles virus strains as cancer therapeutics
    • PMID:21740361
    • Msaouel P, Iankov ID, Dispenzieri A, Galanis E. Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol 2012; 13:1732- 41; PMID:21740361; http://dx. doi. org/10. 2174/ 138920112800958896
    • (2012) Curr Pharm Biotechnol , vol.13 , pp. 1732-1741
    • Msaouel, P.1    Iankov, I.D.2    Dispenzieri, A.3    Galanis, E.4
  • 71
    • 48249118805 scopus 로고    scopus 로고
    • Measles virus as an oncolytic vector platform
    • PMID:18537591
    • Blechacz B, Russell SJ. Measles virus as an oncolytic vector platform. Curr Gene Ther 2008; 8:162-75; PMID:18537591; http://dx. doi. org/10. 2174/ 156652308784746459
    • (2008) Curr Gene Ther , vol.8 , pp. 162-175
    • Blechacz, B.1    Russell, S.J.2
  • 72
    • 58849107795 scopus 로고    scopus 로고
    • Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: An overview
    • PMID:19169959
    • Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009; 11:43-53; PMID:19169959
    • (2009) Curr Opin Mol Ther , vol.11 , pp. 43-53
    • Msaouel, P.1    Dispenzieri, A.2    Galanis, E.3
  • 73
    • 76249123546 scopus 로고    scopus 로고
    • Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
    • PMID:20103634
    • Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ, Jr., Aderca I, Zollman PJ, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70:875-82; PMID:20103634; http://dx. doi. org/ 10. 1158/0008-5472. CAN-09-2762
    • (2010) Cancer Res , vol.70 , pp. 875-882
    • Galanis, E.1    Hartmann, L.C.2    Cliby, W.A.3    Long, H.J.4    Peethambaram, P.P.5    Barrette, B.A.6    Kaur, J.S.7    Haluska, P.J.8    Aderca, I.9    Zollman, P.J.10
  • 75
    • 18644380484 scopus 로고
    • Pathogenicity and immunology of Newcastle disease virus (NVD) in man
    • PMID:14376703
    • Evans AS. Pathogenicity and immunology of Newcastle disease virus (NVD) in man. Am J Public Health Nations Health 1955; 45:742-5; PMID:14376703; http://dx. doi. org/10. 2105/AJPH. 45. 6. 742
    • (1955) Am J Public Health Nations Health , vol.45 , pp. 742-745
    • Evans, A.S.1
  • 76
    • 0037311805 scopus 로고    scopus 로고
    • Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: Non-virulent cleavage site mutants revert to virulence after one passage in chicken brain
    • PMID:12560582
    • de Leeuw OS, Hartog L, Koch G, Peeters BP. Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: non-virulent cleavage site mutants revert to virulence after one passage in chicken brain. J Gen Virol 2003; 84:475-84; PMID:12560582; http://dx. doi. org/10. 1099/ vir. 0. 18714-0
    • (2003) J Gen Virol , vol.84 , pp. 475-484
    • de Leeuw, O.S.1    Hartog, L.2    Koch, G.3    Peeters, B.P.4
  • 77
    • 0033955837 scopus 로고    scopus 로고
    • Newcastle disease virus (NDV): Brief history of its oncolytic strains
    • PMID:10680736
    • Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 2000; 16:1-15; PMID:10680736; http://dx. doi. org/10. 1016/S1386-6532(99)00072-4
    • (2000) J Clin Virol , vol.16 , pp. 1-15
    • Sinkovics, J.G.1    Horvath, J.C.2
  • 79
    • 67349132360 scopus 로고    scopus 로고
    • Genetically engineered Newcastle disease virus for malignant melanoma therapy
    • PMID:19242529
    • Zamarin D, Vigil A, Kelly K, Garcia-Sastre A, Fong Y. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther 2009; 16:796-804; PMID:19242529; http://dx. doi. org/ 10. 1038/gt. 2009. 14
    • (2009) Gene Ther , vol.16 , pp. 796-804
    • Zamarin, D.1    Vigil, A.2    Kelly, K.3    Garcia-Sastre, A.4    Fong, Y.5
  • 80
    • 63949087329 scopus 로고    scopus 로고
    • Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses
    • PMID:19209145
    • Zamarin D, Martinez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, Garcia-Sastre A, Palese P, Fong Y. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 2009; 17:697-706; PMID:19209145; http://dx. doi. org/ 10. 1038/mt. 2008. 286
    • (2009) Mol Ther , vol.17 , pp. 697-706
    • Zamarin, D.1    Martinez-Sobrido, L.2    Kelly, K.3    Mansour, M.4    Sheng, G.5    Vigil, A.6    Garcia-Sastre, A.7    Palese, P.8    Fong, Y.9
  • 81
    • 76349119010 scopus 로고    scopus 로고
    • Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma
    • PMID:19809404
    • Altomonte J, Marozin S, Schmid RM, Ebert O. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 2010; 18:275-84; PMID:19809404; http://dx. doi. org/10. 1038/mt. 2009. 231
    • (2010) Mol Ther , vol.18 , pp. 275-284
    • Altomonte, J.1    Marozin, S.2    Schmid, R.M.3    Ebert, O.4
  • 82
    • 77958059448 scopus 로고    scopus 로고
    • Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma
    • PMID:20858727
    • Silberhumer GR, Brader P, Wong J, Serganova IS, Gonen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther 2010; 9:2761-9; PMID:20858727; http://dx. doi. org/ 10. 1158/1535-7163. MCT-10-0090
    • (2010) Mol Cancer Ther , vol.9 , pp. 2761-2769
    • Silberhumer, G.R.1    Brader, P.2    Wong, J.3    Serganova, I.S.4    Gonen, M.5    Gonzalez, S.J.6    Blasberg, R.7    Zamarin, D.8    Fong, Y.9
  • 83
    • 80053007260 scopus 로고    scopus 로고
    • Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer
    • PMID:21928411
    • Li P, Chen CH, Li S, Givi B, Yu Z, Zamarin D, Palese P, Fong Y, Wong RJ. Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head Neck 2011; 33:1394-9; PMID:21928411; http://dx. doi. org/10. 1002/ hed. 21609
    • (2011) Head Neck , vol.33 , pp. 1394-1399
    • Li, P.1    Chen, C.H.2    Li, S.3    Givi, B.4    Yu, Z.5    Zamarin, D.6    Palese, P.7    Fong, Y.8    Wong, R.J.9
  • 86
    • 84893773791 scopus 로고    scopus 로고
    • Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
    • PMID:24384773
    • Buijs PR, van Eijck CH, Hofland LJ, Fouchier RA, van den Hoogen BG. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Cancer Gene Ther 2014; 21:24-30; PMID:24384773; http://dx. doi. org/ 10. 1038/cgt. 2013. 78
    • (2014) Cancer Gene Ther , vol.21 , pp. 24-30
    • Buijs, P.R.1    van Eijck, C.H.2    Hofland, L.J.3    Fouchier, R.A.4    van den Hoogen, B.G.5
  • 88
    • 84869217555 scopus 로고    scopus 로고
    • Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer
    • PMID:23052398
    • Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol 2012; 93:2529-45; PMID:23052398; http://dx. doi. org/10. 1099/ vir. 0. 046672-0
    • (2012) J Gen Virol , vol.93 , pp. 2529-2545
    • Hastie, E.1    Grdzelishvili, V.Z.2
  • 89
    • 0023724709 scopus 로고
    • A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection
    • PMID:2845825
    • Quiroz E, Moreno N, Peralta PH, Tesh RB. A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am J Trop Med Hyg 1988; 39:312-4; PMID:2845825
    • (1988) Am J Trop Med Hyg , vol.39 , pp. 312-314
    • Quiroz, E.1    Moreno, N.2    Peralta, P.H.3    Tesh, R.B.4
  • 90
    • 0033929057 scopus 로고    scopus 로고
    • Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
    • PMID:10888934
    • Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6:821-5; PMID:10888934; http://dx. doi. org/10. 1038/77558
    • (2000) Nat Med , vol.6 , pp. 821-825
    • Stojdl, D.F.1    Lichty, B.2    Knowles, S.3    Marius, R.4    Atkins, H.5    Sonenberg, N.6    Bell, J.C.7
  • 91
    • 27944432605 scopus 로고    scopus 로고
    • VSV-tumor selective replication and protein translation
    • PMID:16299531
    • Barber GN. VSV-tumor selective replication and protein translation. Oncogene 2005; 24:7710-9; PMID:16299531; http://dx. doi. org/10. 1038/sj. onc. 1209042
    • (2005) Oncogene , vol.24 , pp. 7710-7719
    • Barber, G.N.1
  • 92
    • 44949129955 scopus 로고    scopus 로고
    • Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation
    • PMID:18417567
    • Oliere S, Arguello M, Mesplede T, Tumilasci V, Nakhaei P, Stojdl D, Sonenberg N, Bell J, Hiscott J. Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 2008; 82:5735-49; PMID:18417567; http://dx. doi. org/10. 1128/JVI. 02601-07
    • (2008) J Virol , vol.82 , pp. 5735-5749
    • Oliere, S.1    Arguello, M.2    Mesplede, T.3    Tumilasci, V.4    Nakhaei, P.5    Stojdl, D.6    Sonenberg, N.7    Bell, J.8    Hiscott, J.9
  • 93
    • 84907247400 scopus 로고    scopus 로고
    • Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs
    • PMID:24219832
    • LeBlanc AK, Naik S, Galyon GD, Jenks N, Steele M, Peng KW, Federspiel MJ, Donnell R, Russell SJ. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. Hum Gene Ther Clin Dev 2013; 24:174-81; PMID:24219832; http://dx. doi. org/10. 1089/humc. 2013. 165
    • (2013) Hum Gene Ther Clin Dev , vol.24 , pp. 174-181
    • LeBlanc, A.K.1    Naik, S.2    Galyon, G.D.3    Jenks, N.4    Steele, M.5    Peng, K.W.6    Federspiel, M.J.7    Donnell, R.8    Russell, S.J.9
  • 94
    • 77950957568 scopus 로고    scopus 로고
    • Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates
    • PMID:19911974
    • Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther 2010; 21:451-62; PMID:19911974; http://dx. doi. org/ 10. 1089/hum. 2009. 111
    • (2010) Hum Gene Ther , vol.21 , pp. 451-462
    • Jenks, N.1    Myers, R.2    Greiner, S.M.3    Thompson, J.4    Mader, E.K.5    Greenslade, A.6    Griesmann, G.E.7    Federspiel, M.J.8    Rakela, J.9    Borad, M.J.10
  • 96
    • 79961192841 scopus 로고    scopus 로고
    • A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion
    • PMID:21680501
    • Stanifer ML, Cureton DK, Whelan SP. A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion. J Virol 2011; 85:8105-15; PMID:21680501; http://dx. doi. org/ 10. 1128/JVI. 00735-11
    • (2011) J Virol , vol.85 , pp. 8105-8115
    • Stanifer, M.L.1    Cureton, D.K.2    Whelan, S.P.3
  • 97
    • 84869049988 scopus 로고    scopus 로고
    • Second-site mutations selected in transcriptional regulatory sequences compensate for engineered mutations in the vesicular stomatitis virus nucleocapsid protein
    • PMID:22875970
    • Harouaka D, Wertz GW. Second-site mutations selected in transcriptional regulatory sequences compensate for engineered mutations in the vesicular stomatitis virus nucleocapsid protein. J Virol 2012; 86:11266-75; PMID:22875970; http://dx. doi. org/ 10. 1128/JVI. 01238-12
    • (2012) J Virol , vol.86 , pp. 11266-11275
    • Harouaka, D.1    Wertz, G.W.2
  • 98
    • 0035450256 scopus 로고    scopus 로고
    • Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses
    • PMID:11531419
    • Quinones-Kochs MI, Schnell MJ, Buonocore L, Rose JK. Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses. Virology 2001; 287:427-35; PMID:11531419; http://dx. doi. org/10. 1006/viro. 2001. 1058
    • (2001) Virology , vol.287 , pp. 427-435
    • Quinones-Kochs, M.I.1    Schnell, M.J.2    Buonocore, L.3    Rose, J.K.4
  • 99
    • 33748640372 scopus 로고    scopus 로고
    • Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line
    • PMID:16912309
    • Gao Y, Whitaker-Dowling P, Watkins SC, Griffin JA, Bergman I. Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J Virol 2006; 80:8603-12; PMID:16912309; http://dx. doi. org/ 10. 1128/JVI. 00142-06
    • (2006) J Virol , vol.80 , pp. 8603-8612
    • Gao, Y.1    Whitaker-Dowling, P.2    Watkins, S.C.3    Griffin, J.A.4    Bergman, I.5
  • 100
    • 84865306234 scopus 로고    scopus 로고
    • A single amino acid change resulting in loss of fluorescence of eGFP in a viral fusion protein confers fitness and growth advantage to the recombinant vesicular stomatitis virus
    • PMID:22832124
    • Dinh PX, Panda D, Das PB, Das SC, Das A, Pattnaik AK. A single amino acid change resulting in loss of fluorescence of eGFP in a viral fusion protein confers fitness and growth advantage to the recombinant vesicular stomatitis virus. Virology 2012; 432:460-9; PMID:22832124; http://dx. doi. org/10. 1016/j. virol. 2012. 07. 004
    • (2012) Virology , vol.432 , pp. 460-469
    • Dinh, P.X.1    Panda, D.2    Das, P.B.3    Das, S.C.4    Das, A.5    Pattnaik, A.K.6
  • 101
    • 84875744451 scopus 로고    scopus 로고
    • Hand, foot, and mouth disease: Current scenario and Indian perspective
    • PMID:23442455
    • Sarma N. Hand, foot, and mouth disease: current scenario and Indian perspective. Indian J Dermatol Venereol Leprol 2013; 79:165-75; PMID:23442455; http://dx. doi. org/10. 4103/0378-6323. 107631
    • (2013) Indian J Dermatol Venereol Leprol , vol.79 , pp. 165-175
    • Sarma, N.1
  • 102
    • 0024425960 scopus 로고
    • The complete nucleotide sequence of coxsackievirus A21
    • PMID:2584950
    • Hughes PJ, North C, Minor PD, Stanway G. The complete nucleotide sequence of coxsackievirus A21. J Gen Virol 1989; 70(Pt 11):2943-52; PMID:2584950; http://dx. doi. org/10. 1099/0022- 1317-70-11-2943
    • (1989) J Gen Virol , vol.70 , pp. 2943-2952
    • Hughes, P.J.1    North, C.2    Minor, P.D.3    Stanway, G.4
  • 103
    • 0031008583 scopus 로고    scopus 로고
    • Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry
    • PMID:9151867
    • Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 1997; 71:4736-43; PMID:9151867
    • (1997) J Virol , vol.71 , pp. 4736-4743
    • Shafren, D.R.1    Dorahy, D.J.2    Ingham, R.A.3    Burns, G.F.4    Barry, R.D.5
  • 104
    • 1642453768 scopus 로고    scopus 로고
    • Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21
    • PMID:14734451
    • Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P, Barry RD. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2004; 10:53-60; PMID:14734451; http://dx. doi. org/10. 1158/1078- 0432. CCR-0690-3
    • (2004) Clin Cancer Res , vol.10 , pp. 53-60
    • Shafren, D.R.1    Au, G.G.2    Nguyen, T.3    Newcombe, N.G.4    Haley, E.S.5    Beagley, L.6    Johansson, E.S.7    Hersey, P.8    Barry, R.D.9
  • 106
    • 0024519677 scopus 로고
    • Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily
    • PMID:2538245
    • Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 1989; 56:855-65; PMID:2538245; http://dx. doi. org/10. 1016/0092- 8674(89)90690-9
    • (1989) Cell , vol.56 , pp. 855-865
    • Mendelsohn, C.L.1    Wimmer, E.2    Racaniello, V.R.3
  • 108
    • 78049452625 scopus 로고    scopus 로고
    • MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus
    • PMID:20648000
    • Goetz C, Everson RG, Zhang LC, Gromeier M. MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. Mol Ther 2010; 18:1937- 46; PMID:20648000; http://dx. doi. org/10. 1038/ mt. 2010. 145
    • (2010) Mol Ther , vol.18 , pp. 1937-1946
    • Goetz, C.1    Everson, R.G.2    Zhang, L.C.3    Gromeier, M.4
  • 109
    • 0032935027 scopus 로고    scopus 로고
    • Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence
    • PMID:9882296
    • Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J Virol 1999; 73:958-64; PMID:9882296
    • (1999) J Virol , vol.73 , pp. 958-964
    • Gromeier, M.1    Bossert, B.2    Arita, M.3    Nomoto, A.4    Wimmer, E.5
  • 110
    • 54949090721 scopus 로고    scopus 로고
    • Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype
    • PMID:18766173
    • Dobrikova EY, Broadt T, Poiley-Nelson J, Yang X, Soman G, Giardina S, Harris R, Gromeier M. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther 2008; 16:1865-72; PMID:18766173; http://dx. doi. org/10. 1038/ mt. 2008. 184
    • (2008) Mol Ther , vol.16 , pp. 1865-1872
    • Dobrikova, E.Y.1    Broadt, T.2    Poiley-Nelson, J.3    Yang, X.4    Soman, G.5    Giardina, S.6    Harris, R.7    Gromeier, M.8
  • 112
    • 84857880081 scopus 로고    scopus 로고
    • Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus: Rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis
    • PMID:22171271
    • Dobrikova EY, Goetz C, Walters RW, Lawson SK, Peggins JO, Muszynski K, Ruppel S, Poole K, Giardina SL, Vela EM, et al. Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus: rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. J Virol 2012; 86:2750-9; PMID:22171271; http://dx. doi. org/10. 1128/ JVI. 06427-11
    • (2012) J Virol , vol.86 , pp. 2750-2759
    • Dobrikova, E.Y.1    Goetz, C.2    Walters, R.W.3    Lawson, S.K.4    Peggins, J.O.5    Muszynski, K.6    Ruppel, S.7    Poole, K.8    Giardina, S.L.9    Vela, E.M.10
  • 113
    • 79960397102 scopus 로고    scopus 로고
    • A host-specific, temperature- sensitive translation defect determines the attenuation phenotype of a human rhinovirus/poliovirus chimera, PV1(RIPO)
    • PMID:21561914
    • Jahan N, Wimmer E, Mueller S. A host-specific, temperature- sensitive translation defect determines the attenuation phenotype of a human rhinovirus/poliovirus chimera, PV1(RIPO). J Virol 2011; 85:7225-35; PMID:21561914; http://dx. doi. org/10. 1128/ JVI. 01804-09
    • (2011) J Virol , vol.85 , pp. 7225-7235
    • Jahan, N.1    Wimmer, E.2    Mueller, S.3
  • 115
    • 84880559818 scopus 로고    scopus 로고
    • Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer
    • PMID:23739064
    • Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. J Natl Cancer Inst 2013; 105:1059-65; PMID:23739064; http://dx. doi. org/10. 1093/jnci/ djt130
    • (2013) J Natl Cancer Inst , vol.105 , pp. 1059-1065
    • Poirier, J.T.1    Dobromilskaya, I.2    Moriarty, W.F.3    Peacock, C.D.4    Hann, C.L.5    Rudin, C.M.6
  • 117
    • 79951649714 scopus 로고    scopus 로고
    • A single intravenous injection of oncolytic picornavirus SVV- 001 eliminates medulloblastomas in primary tumorbased orthotopic xenograft mouse models
    • PMID:21075780
    • Yu L, Baxter PA, Zhao X, Liu Z, Wadhwa L, Zhang Y, Su JM, Tan X, Yang J, Adesina A, et al. A single intravenous injection of oncolytic picornavirus SVV- 001 eliminates medulloblastomas in primary tumorbased orthotopic xenograft mouse models. Neuro Oncol 2011; 13:14-27; PMID:21075780; http://dx. doi. org/10. 1093/neuonc/noq148
    • (2011) Neuro Oncol , vol.13 , pp. 14-27
    • Yu, L.1    Baxter, P.A.2    Zhao, X.3    Liu, Z.4    Wadhwa, L.5    Zhang, Y.6    Su, J.M.7    Tan, X.8    Yang, J.9    Adesina, A.10
  • 118
    • 84883168783 scopus 로고    scopus 로고
    • Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumorbased orthotopic xenograft mouse models of pediatric glioma
    • PMID:23658322
    • Liu Z, Zhao X, Mao H, Baxter PA, Huang Y, Yu L, Wadhwa L, Su JM, Adesina A, Perlaky L, et al. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumorbased orthotopic xenograft mouse models of pediatric glioma. Neuro Oncol 2013; 15:1173-85; PMID:23658322; http://dx. doi. org/10. 1093/neuonc/ not065
    • (2013) Neuro Oncol , vol.15 , pp. 1173-1185
    • Liu, Z.1    Zhao, X.2    Mao, H.3    Baxter, P.A.4    Huang, Y.5    Yu, L.6    Wadhwa, L.7    Su, J.M.8    Adesina, A.9    Perlaky, L.10
  • 119
    • 79951821209 scopus 로고    scopus 로고
    • Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features
    • PMID:21304001
    • Rudin CM, Poirier JT, Senzer NN, Stephenson J, Jr., Loesch D, Burroughs KD, Reddy PS, Hann CL, Hallenbeck PL. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res 2011; 17:888-95; PMID:21304001; http://dx. doi. org/10. 1158/1078- 0432. CCR-10-1706
    • (2011) Clin Cancer Res , vol.17 , pp. 888-895
    • Rudin, C.M.1    Poirier, J.T.2    Senzer, N.N.3    Stephenson, J.4    Loesch, D.5    Burroughs, K.D.6    Reddy, P.S.7    Hann, C.L.8    Hallenbeck, P.L.9
  • 120
  • 122
    • 42049121876 scopus 로고    scopus 로고
    • Enhancing poxvirus oncolytic effects through increased spread and immune evasion
    • PMID:18381410
    • Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 2008; 68:2071-5; PMID:18381410; http://dx. doi. org/10. 1158/0008-5472. CAN-07-6515
    • (2008) Cancer Res , vol.68 , pp. 2071-2075
    • Kirn, D.H.1    Wang, Y.2    Liang, W.3    Contag, C.H.4    Thorne, S.H.5
  • 123
    • 36049009021 scopus 로고    scopus 로고
    • Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
    • PMID:17965776
    • Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007; 117:3350- 8; PMID:17965776; http://dx. doi. org/10. 1172/ JCI32727
    • (2007) J Clin Invest , vol.117 , pp. 3350-3358
    • Thorne, S.H.1    Hwang, T.H.2    O'Gorman, W.E.3    Bartlett, D.L.4    Sei, S.5    Kanji, F.6    Brown, C.7    Werier, J.8    Cho, J.H.9    Lee, D.E.10
  • 124
    • 0033950819 scopus 로고    scopus 로고
    • Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant
    • PMID:10678358
    • Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, Bartlett DL. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000; 7:66-73; PMID:10678358; http://dx. doi. org/ 10. 1038/sj. cgt. 7700075
    • (2000) Cancer Gene Ther , vol.7 , pp. 66-73
    • Puhlmann, M.1    Brown, C.K.2    Gnant, M.3    Huang, J.4    Libutti, S.K.5    Alexander, H.R.6    Bartlett, D.L.7
  • 125
    • 38049017526 scopus 로고    scopus 로고
    • Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus
    • PMID:18162040
    • Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007; 4:e353; PMID:18162040; http://dx. doi. org/ 10. 1371/journal. pmed. 0040353
    • (2007) PLoS Med , vol.4
    • Kirn, D.H.1    Wang, Y.2    Le Boeuf, F.3    Bell, J.4    Thorne, S.H.5
  • 126
    • 0024205331 scopus 로고
    • Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene
    • PMID:3184271
    • Shida H, Hinuma Y, Hatanaka M, Morita M, Kidokoro M, Suzuki K, Maruyama T, Takahashi-Nishimaki F, Sugimoto M, Kitamura R, et al. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J Virol 1988; 62:4474-80; PMID:3184271
    • (1988) J Virol , vol.62 , pp. 4474-4480
    • Shida, H.1    Hinuma, Y.2    Hatanaka, M.3    Morita, M.4    Kidokoro, M.5    Suzuki, K.6    Maruyama, T.7    Takahashi-Nishimaki, F.8    Sugimoto, M.9    Kitamura, R.10
  • 127
    • 0016066489 scopus 로고
    • Immunotherapy of malignant melanoma with vaccinia virus
    • PMID:4828533
    • Roenigk HH, Jr., Deodhar S, St Jacques R, Burdick K. Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 1974; 109:668-73; PMID:4828533; http://dx. doi. org/10. 1001/ archderm. 1974. 01630050014003
    • (1974) Arch Dermatol , vol.109 , pp. 668-673
    • Roenigk, H.H.1    Deodhar, S.2    St Jacques, R.3    Burdick, K.4
  • 128
    • 0028233204 scopus 로고
    • Intravesical gene therapy: In vivo gene transfer using recombinant vaccinia virus vectors
    • PMID:8012943
    • Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res 1994; 54:3325-8; PMID:8012943
    • (1994) Cancer Res , vol.54 , pp. 3325-3328
    • Lee, S.S.1    Eisenlohr, L.C.2    McCue, P.A.3    Mastrangelo, M.J.4    Lattime, E.C.5
  • 129
    • 78649519141 scopus 로고    scopus 로고
    • Oncolytic vaccinia virus: A silver bullet?
    • PMID:21105770
    • Lusky M, Erbs P, Foloppe J, Acres RB. Oncolytic vaccinia virus: a silver bullet? Expert Rev Vaccines 2010; 9:1353-6; PMID:21105770; http://dx. doi. org/ 10. 1586/erv. 10. 137
    • (2010) Expert Rev Vaccines , vol.9 , pp. 1353-1356
    • Lusky, M.1    Erbs, P.2    Foloppe, J.3    Acres, R.B.4
  • 132
    • 0037458734 scopus 로고    scopus 로고
    • Smallpox vaccination and adverse reactions. Guidance for clinicians
    • PMID:12617510
    • Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003; 52:1-28; PMID:12617510
    • (2003) MMWR Recomm Rep , vol.52 , pp. 1-28
    • Cono, J.1    Casey, C.G.2    Bell, D.M.3
  • 134
    • 84899063595 scopus 로고    scopus 로고
    • Genome scale patterns of recombination between coinfecting vaccinia viruses
    • PMID:24574414
    • Qin L, Evans DH. Genome scale patterns of recombination between coinfecting vaccinia viruses. J Virol 2014; 88:5277-86; PMID:24574414; http://dx. doi. org/10. 1128/JVI. 00022-14
    • (2014) J Virol , vol.88 , pp. 5277-5286
    • Qin, L.1    Evans, D.H.2
  • 135
    • 0002402597 scopus 로고
    • Reovirus infections in human volunteers
    • PMID:13974840
    • Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963; 77:29-37; PMID:13974840
    • (1963) Am J Hyg , vol.77 , pp. 29-37
    • Rosen, L.1    Evans, H.E.2    Spickard, A.3
  • 136
    • 17044431352 scopus 로고    scopus 로고
    • Prevalence of reovirusspecific antibodies in young children in Nashville, Tennessee
    • PMID:15776366
    • Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE, Jr., Dermody TS. Prevalence of reovirusspecific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005; 191:1221-4; PMID:15776366; http://dx. doi. org/10. 1086/428911
    • (2005) J Infect Dis , vol.191 , pp. 1221-1224
    • Tai, J.H.1    Williams, J.V.2    Edwards, K.M.3    Wright, P.F.4    Crowe, J.E.5    Dermody, T.S.6
  • 137
    • 84871390091 scopus 로고    scopus 로고
    • Reovirus: A targeted therapeutic-progress and potential
    • PMID:23038811
    • Maitra R, Ghalib MH, Goel S. Reovirus: a targeted therapeutic-progress and potential. Mol Cancer Res 2012; 10:1514-25; PMID:23038811; http://dx. doi. org/10. 1158/1541-7786. MCR-12-0157
    • (2012) Mol Cancer Res , vol.10 , pp. 1514-1525
    • Maitra, R.1    Ghalib, M.H.2    Goel, S.3
  • 138
    • 27944459718 scopus 로고    scopus 로고
    • Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer
    • PMID:16299532
    • Shmulevitz M, Marcato P, Lee PW. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 2005; 24:7720-8; PMID:16299532; http://dx. doi. org/ 10. 1038/sj. onc. 1209041
    • (2005) Oncogene , vol.24 , pp. 7720-7728
    • Shmulevitz, M.1    Marcato, P.2    Lee, P.W.3
  • 139
    • 34547125563 scopus 로고    scopus 로고
    • Uncoating reo: Uncovering the steps critical for oncolysis
    • PMID:17646836
    • Lemay G, Tumilasci V, Hiscott J. Uncoating reo: uncovering the steps critical for oncolysis. Mol Ther 2007; 15:1406-7; PMID:17646836; http://dx. doi. org/10. 1038/sj. mt. 6300242
    • (2007) Mol Ther , vol.15 , pp. 1406-1407
    • Lemay, G.1    Tumilasci, V.2    Hiscott, J.3
  • 141
    • 84868103303 scopus 로고    scopus 로고
    • Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A
    • PMID:23110175
    • van den Wollenberg DJ, Dautzenberg IJ, van den Hengel SK, Cramer SJ, de Groot RJ, Hoeben RC. Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A. PLoS One 2012; 7:e48064; PMID:23110175; http://dx. doi. org/10. 1371/journal. pone. 0048064
    • (2012) PLoS One , vol.7
    • van den Wollenberg, D.J.1    Dautzenberg, I.J.2    van den Hengel, S.K.3    Cramer, S.J.4    de Groot, R.J.5    Hoeben, R.C.6
  • 143
    • 77953539465 scopus 로고    scopus 로고
    • Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
    • PMID:20223697
    • Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010; 21:91-8; PMID:20223697; http://dx. doi. org/ 10. 1016/j. cytogfr. 2010. 02. 006
    • (2010) Cytokine Growth Factor Rev , vol.21 , pp. 91-98
    • Harrington, K.J.1    Vile, R.G.2    Melcher, A.3    Chester, J.4    Pandha, H.S.5
  • 144
    • 84894380172 scopus 로고    scopus 로고
    • Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production
    • PMID:24419798
    • Chakrabarty R, Tran H, Fortin Y, Yu Z, Shen SH, Kolman J, Onions D, Voyer R, Hagerman A, Serl S, et al. Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production. Appl Microbiol Biotechnol 2014; 98:1763-70; PMID:24419798; http://dx. doi. org/10. 1007/s00253- 013-5499-0
    • (2014) Appl Microbiol Biotechnol , vol.98 , pp. 1763-1770
    • Chakrabarty, R.1    Tran, H.2    Fortin, Y.3    Yu, Z.4    Shen, S.H.5    Kolman, J.6    Onions, D.7    Voyer, R.8    Hagerman, A.9    Serl, S.10
  • 147
    • 0034947740 scopus 로고    scopus 로고
    • Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary
    • PMID:11435579
    • Logg CR, Logg A, Tai CK, Cannon PM, Kasahara N. Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary. J Virol 2001; 75:6989-98; PMID:11435579; http://dx. doi. org/10. 1128/ JVI. 75. 15. 6989-6998. 2001
    • (2001) J Virol , vol.75 , pp. 6989-6998
    • Logg, C.R.1    Logg, A.2    Tai, C.K.3    Cannon, P.M.4    Kasahara, N.5
  • 148
    • 79952193873 scopus 로고    scopus 로고
    • Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma
    • PMID:20623247
    • Hlavaty J, Jandl G, Liszt M, Petznek H, Konig-Schuster M, Sedlak J, Egerbacher M, Weissenberger J, Salmons B, Gunzburg WH, et al. Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol 2011; 102:59-69; PMID:20623247; http://dx. doi. org/10. 1007/s11060- 010-0295-5
    • (2011) J Neurooncol , vol.102 , pp. 59-69
    • Hlavaty, J.1    Jandl, G.2    Liszt, M.3    Petznek, H.4    Konig-Schuster, M.5    Sedlak, J.6    Egerbacher, M.7    Weissenberger, J.8    Salmons, B.9    Gunzburg, W.H.10
  • 149
    • 84867077136 scopus 로고    scopus 로고
    • Design and selection of Toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression
    • PMID:22547150
    • Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 2012; 20:1689-98; PMID:22547150; http://dx. doi. org/10. 1038/mt. 2012. 83
    • (2012) Mol Ther , vol.20 , pp. 1689-1698
    • Perez, O.D.1    Logg, C.R.2    Hiraoka, K.3    Diago, O.4    Burnett, R.5    Inagaki, A.6    Jolson, D.7    Amundson, K.8    Buckley, T.9    Lohse, D.10
  • 150
    • 79960556047 scopus 로고    scopus 로고
    • Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma
    • PMID:21660062
    • Kawasaki Y, Tamamoto A, Takagi-Kimura M, Maeyama Y, Yamaoka N, Terada N, Okamura H, Kasahara N, Kubo S. Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma. Cancer Gene Ther 2011; 18:571-8; PMID:21660062; http://dx. doi. org/10. 1038/ cgt. 2011. 25
    • (2011) Cancer Gene Ther , vol.18 , pp. 571-578
    • Kawasaki, Y.1    Tamamoto, A.2    Takagi-Kimura, M.3    Maeyama, Y.4    Yamaoka, N.5    Terada, N.6    Okamura, H.7    Kasahara, N.8    Kubo, S.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.